Needham & Company LLC Issues Positive Forecast for Liquidia (NASDAQ:LQDA) Stock Price

Liquidia (NASDAQ:LQDA) had its price objective upped by equities researchers at Needham & Company LLC from $52.00 to $54.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 56.43% from the stock’s current price.

Other research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. HC Wainwright upped their price target on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday. Finally, BTIG Research reiterated a “buy” rating and issued a $49.00 price target on shares of Liquidia in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.56.

Liquidia Stock Up 0.4%

Liquidia stock opened at $34.52 on Thursday. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. Liquidia has a 1-year low of $11.26 and a 1-year high of $46.67. The company has a fifty day simple moving average of $37.07 and a 200 day simple moving average of $30.84. The company has a market cap of $3.00 billion, a P/E ratio of -23.97, a price-to-earnings-growth ratio of 0.60 and a beta of 0.52.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The business had revenue of $92.02 million for the quarter. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.Liquidia’s quarterly revenue was up 3072.4% compared to the same quarter last year. Research analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity

In other Liquidia news, CFO Michael Kaseta sold 36,932 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,382,364.76. Following the transaction, the chief financial officer directly owned 350,919 shares in the company, valued at $13,134,898.17. The trade was a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev Saggar sold 21,142 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $791,345.06. Following the completion of the transaction, the insider directly owned 176,883 shares in the company, valued at $6,620,730.69. The trade was a 10.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 212,534 shares of company stock valued at $7,964,719. 26.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the fourth quarter valued at approximately $25,000. NewEdge Advisors LLC bought a new stake in Liquidia in the 2nd quarter valued at $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Liquidia in the 3rd quarter valued at $30,000. FNY Investment Advisers LLC acquired a new position in Liquidia in the 3rd quarter valued at $34,000. Finally, Covestor Ltd increased its position in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported robust YUTREPIA uptake, $148.3M net product sales for 2025, $90.1M in Q4, a second consecutive profitable quarter and $190.7M cash — a clear commercialization win that supports longer-term revenue visibility. Read More.
• Positive Sentiment: HC Wainwright materially raised multi-year earnings forecasts (FY2026–FY2029) and lifted near-term Q4 estimates — analyst bullishness can underpin upside as sell-side models shift higher. Read More.
• Neutral Sentiment: Transcript and call highlights show management emphasizing rapid prescriber adoption, plans to expand the sales force and fund development from operations — useful context for investors but not an immediate catalyst. Read More.
• Neutral Sentiment: Market commentary and valuation pieces weigh whether the post-launch run-up leaves room for further gains; this shapes investor positioning (buyers vs. profit-takers). Read More.
• Negative Sentiment: Shares gapped down in pre-market trading after the quarter amid perceptions the $0.15 EPS print failed to meet some consensus targets; that short-term disappointment drove selling pressure. Read More.
• Negative Sentiment: Despite strong sales, reporting differences vs. certain consensus figures (and a mixed presentation of GAAP vs. non‑GAAP metrics) created confusion and volatility around the print. Read More.
• Negative Sentiment: Notable insider and institutional selling (Quiver/SEC filings) and a reported $5.1M manager sale add near-term supply pressure and may weigh on sentiment until clearer follow-through from sales growth. Read More. Read More.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).